Quarterly report [Sections 13 or 15(d)]

Consolidated Statements of Operations (Unaudited)

v3.26.1
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement [Abstract]    
Net revenues
Operating expenses    
General and administrative 3,618 870
Total operating expenses 3,618 870
Net loss from operations (3,618) (870)
Interest expense, net (131) (91)
Loss on remeasurement of derivative liability (227)
Equity income from DNA X LLC 48
Net loss from continuing operations before income taxes (3,928) (961)
Income tax expense from continuing operations
Net loss from continuing operations (3,928) (961)
Discontinued Operations:    
Income from discontinued operations, net of tax 10,268 1,419
Net income $ 6,340 $ 458
Net earnings (loss) per share basic and diluted:    
Net loss per share basic, Continuing operations [1] $ (3.11) $ (2.96)
Net loss per share diluted, Continuing operations [1] (3.11) (2.96)
Net loss per share basic, Discontinued operations [1] 8.12 4.37
Net loss per share diluted, Discontinued operations [1] 8.12 4.37
Net loss per share basic, Net loss [1] 5.01 1.41
Net loss per share diluted, Net loss [1] $ 5.01 $ 1.41
Weighted-average shares used in computing net loss per share:    
Weighted-average shares used in computing net loss per share, basic [1] 1,265,067 324,431
Weighted-average shares used in computing net loss per share, diluted [1] 1,265,067 324,431
[1] Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025, see Note 1.